Earnings Call Insights: Daré Bioscience (DARE) Q1 2026 Management View "We will review our financial results, provide updates on our clinical pipeline and discuss the continued execution of our expanded business strategy" (Chief Accounting Officer MarDee Haring-Layton), adding that the strategy includes "a dual path approach, commercializing proprietary formulations through 503B compounding while ...
Earnings Call Insights: Daré Bioscience (DARE) Q1 2026 Management View "We will review our financial results, provide updates on our clinical pipeline and discuss the continued execution of our expanded business strategy" (Chief Accounting Officer MarDee Haring-Layton), adding that the strategy includes "a dual path approach, commercializing proprietary formulations through 503B compounding while pursuing FDA approval, and advancing select solutions as branded consumer health products that do not require a prescription." "The pre-fulfillment prescribing for DARE to PLAY sildenafil cream ... has been live across 50 states since February 2026" (CEO Sabrina Johnson), and she said Bravado "targeting dispensing to begin this summer as they continue to complete the necessary state licensing and fulfillment preparations." "Flora Sync LF5 ... we are launching commercially in June of 2026" (CEO Johnson), and she added, "We begin to expect recording revenue from Flora Sync LF5 in June. And this will mark the first time that we have recorded direct product revenue as a company." "Earlier this week, we announced positive interim results from our ongoing Phase III clinical trial" (CEO Johnson) for Ovaprene, stating the DSMB "recommended the study continue without modification for the second time" and that "approximately 9% of women treated in the study had experienced a pregnancy." "We ended the quarter with approximately $18.5 million in cash and cash equivalents and working capital of approximately $0.5 million" (Chief Accounting Officer Haring-Layton), and she said "SG&A expenses for the first quarter of 2026 were approximately $2.2 million" and "R&D expenses were approximately $0.7 million," while emphasizing that "grant funding directly offsets our reported R&D costs" and "contra R&D expense related to grant funding was approximately $3.5 million." Outlook "We expect to begin recording product revenue from DARE to PLAY in the third quarter of 2026" (Chief Accounting Officer...
According to its SEC filing dated May 13, 2026, Bienville Capital Management sold all 945,332 shares of GitLab (NASDAQ:GTLB) . The estimated value of this transaction, based on the average closing price for the first quarter, was $27.61 million. The quarter-end value of the GitLab position dropped by $35.48 million, a figure that includes both the trading activity and underlying stock price change...
According to its SEC filing dated May 13, 2026, Bienville Capital Management sold all 945,332 shares of GitLab (NASDAQ:GTLB) . The estimated value of this transaction, based on the average closing price for the first quarter, was $27.61 million. The quarter-end value of the GitLab position dropped by $35.48 million, a figure that includes both the trading activity and underlying stock price changes. GitLab Inc. is a leading provider of DevOps lifecycle software, enabling organizations to enhance productivity and accelerate software delivery. Its unified platform addresses the growing demand for integrated development and security solutions, supporting a diverse global client base and maintaining a competitive edge in the software application industry. When an asset manager sells its entire stake in a company that was previously its No. 4 holding, investors may wonder whether they should do the same. So, is Bienville’s sale of GitLab worth noting? Continue reading